University of Florida Proton Therapy Institute response to prostate cancer treatment comparison published Dec. 13, 2012 in the Journal of the National Cancer Institute

December 14, 2012

Download This Press Release

This type of retrospective study based on surrogate data and insufficient follow-up lacks the scientific rigor needed to draw meaningful conclusions about proton therapy.

It is more useful to look at prospective data – actual outcomes reported by both patients and their providers. We are actively engaged in prospective studies on prostate cancer and many other disease sites. The early data, based on actual prostate cancer patient outcomes after 5 years, suggests that proton therapy is both safe and effective treatment.

• 99 percent cancer progression-free survival in low and intermediate risk prostate cancer patients 1
• 74 percent cancer progression-free survival in high risk prostate cancer patients 2
• Minimal bowel and urinary side effects that return to pre-treatment levels or improve upon pre-treatment levels within 2 years of treatment. 1, 2, 3, 4
• Minimal impact on sexual function with decrease in erectile function in the first year that stabilizes in years 2 and 3. 4
These data were reported at ASTRO 2012 and abstracts are available in the Red Journal published for the conference proceedings.

We expect a more complete report of this data to be published soon. We are confident that our data will move the conversation forward for proton therapy and its positive impact on both eliminating cancer and preserving excellent quality of life for men – improving on the results for any other type of prostate cancer treatment available today.  

Mendenhall NP, Li Z, Hoppe BS, Marcus RB, Mendenhall WM, Nichols RC, Morris CG, Williams CR, Costa J, Henderson R.  The Value of Dose Constraints in Minimizing Rectal Toxicity in Patients Receiving Radiation Therapy for Prostate Cancer: Three-Year Analysis of Toxicity Outcomes in 2 Prospective Trials of Image-Guided Proton Therapy for Early- And Intermediate-Risk Prostate Cancer; ASTRO 54: Poster Presentation 2441
Mendenhall NP, Hoppe BS, Nichols RC, Mendenhall WM, Marcus RB, Morris CG, Li Z, Williams CR, Costa J, Henderson R.  Early Patterns of Failure in a Prospective Trial of Concomitant Docetaxel and Proton Therapy for High-Risk Prostate Cancer; ASTRO 54: Oral Presentation 226
Henderson RH, Li Z, Hoppe BS, Marcus RB, Mendenhall WM, Nichols RC, Morris CG, Williams CR, Costa J, Mendenhall NP. Three-year Analysis of Urinary Toxicity in Two Prospective Trials of Image-guided Proton Therapy for Early- and Intermediate-Risk Prostate Cancer: Outcomes in Men with Moderate to Severe Pretreatment Urinary Obstructive Symptoms; ASTRO 54: Poster Presentation 2514
Hoppe BS, Nichols RC, Henderson R, Mendenhall WM, Williams C, Costa J, Morris CG, Su Z, Li Z, Mendenhall NP. Patient-Reported Quality of Life Following Treatment of Prostate Cancer with Proton Therapy. ; ASTRO 54: Poster Presentation 1119


Download This Press Release

< View All Press Releases